![](/img/cover-not-exists.png)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Di Leo, Angelo, Johnston, Stephen, Lee, Keun Seok, Ciruelos, Eva, Lønning, Per E, Janni, Wolfgang, O'Regan, Ruth, Mouret-Reynier, Marie-Ange, Kalev, Dimitar, Egle, Daniel, Csőszi, Tibor, Bordonaro, RoLanguage:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(17)30688-5
Date:
December, 2017
File:
PDF, 596 KB
english, 2017